Amphista Therapeutics rakes in $7.5m Series A

UK-based Amphista Therapeutics, a biopharmaceutical company, has raised $7.5 million in Series A funding.

UK-based Amphista Therapeutics, a biopharmaceutical company, has raised $7.5 million in Series A funding. Advent Life Sciences led the round with participation from other investors that included the Scottish Investment Bank and BioMotiv.

Source: Press Release